Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 106

Sort by

Sort Order Select

Journal Articles

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML:a randomized, placebo-controlled study by the ALLG

Blood blood.2023020301.

https://doi.org/10.1182/blood.2023020301

Published: 2023

Includes: Supplemental data

Journal Articles

Multi-Omic Single-Cell Sequencing Reveals Genetic and Immunophenotypic Clonal Selection in Patients With FLT3-Mutated AML Treated With Gilteritinib/Venetoclax

Vanessa E. Kennedy, Cheryl Peretz, Paul Lee, Brenda Chyla, Yan Sun, Monique Dail, Jason Hill, Elaine Tran, Andrew Koh, Jessica K. Altman, Naval Daver, Mark J. Levis, James McCloskey, Alexander Perl, Catherine Smith

Blood (2022) 140 (Supplement 1): 2244–2246.

https://doi.org/10.1182/blood-2022-160304

Published: 2022

Journal Articles

Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3 -Internal Tandem Duplication: Results from the Quantum-First Trial

Blood (2022) 140 (Supplement 1): 2130–2132.

https://doi.org/10.1182/blood-2022-169011

Published: 2022

Journal Articles

Engaging Continuing Medical Education Reveals Persisting Knowledge and Practice Gaps in FLT3-Positve AML

Katie Robinson, Jillian Scavone Scavone, Emily Scully, Will Cioffi, Robert A. Esgro, Mark J. Levis

Blood (2022) 140 (Supplement 1): 13132.

https://doi.org/10.1182/blood-2022-157187

Published: 2022

Journal Articles

Impact of Inotuzumb Ozogamicin on Outcome in Relapsed or Refractory Acute B-Lymphoblastic Leukemia Patients Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Sabine Kayser, Chiara Sartor, Fabio Giglio, Alessandro Bruno, Jonathan Webster, Mark J. Levis, Richard F. Schlenk, Cristina Papayannidis

Blood (2022) 140 (Supplement 1): 8906–8907.

https://doi.org/10.1182/blood-2022-166193

Published: 2022

Journal Articles

V-FAST Master Trial: Subgroup Analysis of Outcomes with CPX-351 Plus Midostaurin in Adults with Newly Diagnosed Acute Myeloid Leukemia By FLT3 Mutation Type

James McCloskey, Vinod A. Pullarkat, Gabriel N. Mannis, Tara L. Lin, Stephen A Strickland, Amir T. Fathi, Stefan Faderl, Divya Chakravarthy, Yana Lutska, Vijayalakshmi Chandrasekaran, Ronald S. Cheung, Mark J. Levis

Blood (2022) 140 (Supplement 1): 3312–3314.

https://doi.org/10.1182/blood-2022-159680

Published: 2022

Journal Articles

Gemtuzumab Ozogamicin for Cytoreduction in Hyperleukocytosis

Matthew Scarlotta, Jonathan Webster, Matthew Newman, Cory Schulz, Kristin Stokvis, Alexander J. Ambinder, Tania Jain, William Brian Dalton, Lukasz P. Gondek, Gabrielle T. Prince, Gabriel Ghiaur, Christopher S. Hourigan, Amy E. DeZern, Ivana Gojo, Jonathan Allen Webster, Mark J. Levis

Blood (2022) 140 (Supplement 1): 11747–11748.

https://doi.org/10.1182/blood-2022-160300

Published: 2022

Journal Articles

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Blood (2022) 140 (Supplement 1): 4813–4815.

https://doi.org/10.1182/blood-2022-171038

Published: 2022

Journal Articles

Quantum-First Trial: FLT3 -ITD-Specific MRD Clearance Is Associated with Improved Overall Survival

Blood (2022) 140 (Supplement 1): 546–548.

https://doi.org/10.1182/blood-2022-162739

Published: 2022

Journal Articles

Outcomes of Patients with TP53 -Mutated Myeloid Neoplasms (TP53-MN) and the Role of Allogenic Blood or Marrow Transplantation (alloBMT)

Sergiu Pasca, Saurav D. Haldar, Alexander J. Ambinder, Jonathan Webster, Tania Jain, William Brian Dalton, Gabrielle T. Prince, Gabriel Ghiaur, Amy E. DeZern, Ivana Gojo, Jonathan Allen Webster, Cory Schulz, Kristin Stokvis, Mark J. Levis, Richard J. Jones, Lukasz P. Gondek

Blood (2022) 140 (Supplement 1): 10629–10631.

https://doi.org/10.1182/blood-2022-169148

Published: 2022

Journal Articles

Follow-up of patients with R/R FLT3- mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Blood (2022) 139 (23): 3366–3375.

https://doi.org/10.1182/blood.2021011583

Published: 2022

Includes: Supplemental data

Journal Articles

Coagulopathy, Hypoxemia, and Mortality Outcomes in Newly Diagnosed Acute Myeloid Leukemia with Hyperleukocytosis Treated with Large Volume Leukapheresis

Bryan Hambley, MD, Eric Gehrie, Jonathan Webster, MD, Margaret M. Showel, MD, Lukasz P. Gondek, MD PhD, William Brian Dalton, MD PhD, Gabrielle T. Prince, MD, Douglas E Gladstone, MD, Ivana Gojo, MD, Gabriel Ghiaur, MD PhD, Keith W. Pratz, MD, B. Douglas Smith, MD, Amy E. DeZern, MD, Mark J. Levis, MD

Blood (2019) 134 (Supplement_1): 3841.

https://doi.org/10.1182/blood-2019-123229

Published: 2019

Journal Articles

Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Siddhartha Ganguly, MD, Alwin Krämer, MD, Mark J. Levis, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Youngsook Choi, MD, Jeanne Mendell, PhD MPH, Ruth Namuyinga, MD MPH, Hoang Pham, PharmD, Nabil Said, MD MPH, Yibin Wang, PhD, Tsvetomir Mitov, MD, Ben Kim, PharmD, Samer K. Khaled, MD

Blood (2019) 134 (Supplement_1): 1372.

https://doi.org/10.1182/blood-2019-121762

Published: 2019

Journal Articles

A Novel Combination Regimen of BET and FLT3 Inhibition for FLT3-ITD Acute Myeloid Leukemia

Lauren Lee, Yoshiyuki Hizukuri, Paul Severson, Ben Powell, PhD, Chao Zhang, PhD, Yan Ma, Maiko Narahara, Hiroyuki Sumi, PhD, Gideon Bollag, PhD, Mark J. Levis, MD

Blood (2019) 134 (Supplement_1): 1373.

https://doi.org/10.1182/blood-2019-124030

Published: 2019

Journal Articles

Single Cell Sequencing Reveals Evolution of Tumor Heterogeneity of Acute Myeloid Leukemia on Quizartinib

Cheryl A Cohler Peretz, MD, Lisa H F McGary, Tanya F Kumar, J Hunter Jackson, Jose Jacob, Robert Durruthy-Durruthy, PhD, Chunxiao Zhang, Mark J. Levis, MD, Alexander E. Perl, MD, Anskar Yu Hung Leung, MD PhD, Catherine C. Smith, MD

Blood (2019) 134 (Supplement_1): 1440.

https://doi.org/10.1182/blood-2019-132105

Published: 2019

Journal Articles

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Blood (2019) 134 (Supplement_1): 831.

https://doi.org/10.1182/blood-2019-126065

Published: 2019

Journal Articles

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Catherine C. Smith, MD, Mark J. Levis, MD, Alexander E. Perl, MD, Giovanni Martinelli, MD, Andreas Neubauer, MD, Ellin Berman, MD, Pau Montesinos, MD PhD, Maria R. Baer, MD, Richard A. Larson, MD, Wen-Chien Chou, MD, PhD, Hisayuki Yokoyama, MD PhD, Christian Recher, MD PhD, Sung-Soo Yoon, MD PhD, Jason E. Hill, Matt Rosales, Erkut Bahceci

Blood (2019) 134 (Supplement_1): 14.

https://doi.org/10.1182/blood-2019-122620

Published: 2019

Journal Articles

Clinical Outcomes and Characteristics of Patients (pts) with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial

Siddhartha Ganguly, MD, Jorge E. Cortes, MD, Alwin Krämer, MD, Mark J. Levis, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Meena Arunachalam, PharmD, Guy Gammon, MBBS, MRCP, Arnaud Lesegretain, Derek E. Mires, PharmD, Ruth Namuyinga, MD MPH, Yufen Zhang, PhD, Samer K. Khaled, MD

Blood (2019) 134 (Supplement_1): 736.

https://doi.org/10.1182/blood-2019-124504

Published: 2019

Journal Articles

Effect of Co-Mutations and FLT3 -ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 737.

https://doi.org/10.1182/blood-2019-121880

Published: 2019

Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 832.

https://doi.org/10.1182/blood-2019-127345

Published: 2019

NARROW

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML:a randomized, placebo-controlled study by the ALLG

Multi-Omic Single-Cell Sequencing Reveals Genetic and Immunophenotypic Clonal Selection in Patients With FLT3-Mutated AML Treated With Gilteritinib/Venetoclax

Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3 -Internal Tandem Duplication: Results from the Quantum-First Trial

Engaging Continuing Medical Education Reveals Persisting Knowledge and Practice Gaps in FLT3-Positve AML

Impact of Inotuzumb Ozogamicin on Outcome in Relapsed or Refractory Acute B-Lymphoblastic Leukemia Patients Prior to Allogeneic Hematopoietic Stem Cell Transplantation

V-FAST Master Trial: Subgroup Analysis of Outcomes with CPX-351 Plus Midostaurin in Adults with Newly Diagnosed Acute Myeloid Leukemia By FLT3 Mutation Type

Gemtuzumab Ozogamicin for Cytoreduction in Hyperleukocytosis

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Quantum-First Trial: FLT3 -ITD-Specific MRD Clearance Is Associated with Improved Overall Survival

Outcomes of Patients with TP53 -Mutated Myeloid Neoplasms (TP53-MN) and the Role of Allogenic Blood or Marrow Transplantation (alloBMT)

Follow-up of patients with R/R FLT3- mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Coagulopathy, Hypoxemia, and Mortality Outcomes in Newly Diagnosed Acute Myeloid Leukemia with Hyperleukocytosis Treated with Large Volume Leukapheresis

Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

A Novel Combination Regimen of BET and FLT3 Inhibition for FLT3-ITD Acute Myeloid Leukemia

Single Cell Sequencing Reveals Evolution of Tumor Heterogeneity of Acute Myeloid Leukemia on Quizartinib

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Clinical Outcomes and Characteristics of Patients (pts) with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial

Effect of Co-Mutations and FLT3 -ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only